# Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

> **NCT03113760** · PHASE3 · COMPLETED · sponsor: **AB2 Bio Ltd.** · enrollment: 15 (actual)

## Conditions studied

- NLRC4-MAS
- XIAP Deficiency

## Interventions

- **DRUG:** Tadekinig alfa
- **OTHER:** 0.9% sodium chloride

## Key facts

- **NCT ID:** NCT03113760
- **Lead sponsor:** AB2 Bio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-21
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-11-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113760, "Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03113760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*